Target intelligence / Profile preview

Cyclin and CBS domain divalent metal cation transport mediator 1 (CNNM1)

Target
CNNM1
Molecular classification
Transporter, Ion channel-related, Ancient conserved domain protein (ACDP) family
01

Overview

Cyclin and CBS domain divalent metal cation transport mediator 1 (CNNM1) is a member of the CNNM/ACDP (Ancient conserved domain protein) family, predominantly functioning as a divalent cation (notably magnesium) transporter or regulator within cells[1][2][4][5]. CNNM1 contains four main domains: an extracellular domain, a transmembrane region, a cystathionine-β-synthase (CBS) pair domain, and a cyclic nucleotide-binding homology domain[1][4]. It is primarily expressed in the testis and brain, with lower levels in other tissues, and is implicated in maintenance of magnesium homeostasis, copper binding, and germ cell differentiation[4][5]. Mutations in CNNM1 are associated with inherited diseases such as Jalili syndrome, familial hypomagnesemia, and have also been implicated in cancer development and metastasis, as well as in other disorders[3][4][5]. Its exact transport function remains under study, with evidence suggesting both direct and regulatory roles in cation trafficking[1][4]. No established drugs or mechanism-based interacting therapies are currently described for CNNM1, but the protein is under investigation as a potential therapeutic target in oncology and metabolic disease models.

Other names
Metal transporter CNNM1ACDP1SLC70A1Ancient conserved domain-containing protein 1Cyclin-M1CLP-1CNNM1phCNNM1Q9NRU3
02

Biological functions

Magnesium homeostasisDivalent cation transportRegulation of germ cell division and differentiationPotential copper bindingCell proliferation
03

Disease associations

Genetic diseases (e.g. Jalili syndrome, familial hypomagnesemia)Cancer (tumor growth and metastasis)Neuropathologic disordersInfertilityAltered blood pressure
04

Safety considerations

Limited knowledge regarding direct druggable interactionfunctions in essential cation homeostasis, so potential for systemic side effects if perturbedtissue roles in testis and brain may carry specific risks
05

Biomarkers

Mutations associated with hypomagnesemia (e.g. familial hypomagnesemia, Jalili syndrome)potential utility in cancers, but no established clinical biomarkers

Beyond the preview

Go deeper on Cyclin and CBS domain divalent metal cation transport mediator 1 (CNNM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin and CBS domain divalent metal cation transport mediator 1 (CNNM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call